Abstract
The incidence of cutaneous malignant melanoma continues to rise. Strategies to reduce mortality in this situation include improving therapy, encouraging earlier diagnosis, and promoting prevention. New developments such as epiluminescence, sentinel node biopsy, arterial limb perfusion and the use of vaccines are discussed in this context.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McLeod RG (1988) Control of melanoma in high-risk populations. Pigment Cell 9: 131–139
MacKie RM, Osterlind A, Ruiter D, Fritsch P, Aapro M, Cesarini J-P, et al. (1988) Report on Consensus Meeting of the EORTC Melanoma Group on educational needs for primary and secondary prevention of melanoma in Europe. Eur J Cancer 27: 1317–1323
Koh HK, Lew RA, Prout MN (1989) Continuing medical education: screening for melanoma/skin cancer: theoretic and practical considerations. J Am Acad Dermatol 20: 160–172
MacKie RM (1971) An aid to the preoperative assessment of pigmented lesions of the skin. Br J Dermatol 85: 232–238
Pehamberger H, Steiner A, Wolff K (1987) In vivo epiluminescence microscopy of pigmented skin lesions. 1. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 17: 571–583
Steiner A, Pehamberger H, Wolff K (1987) In vivo epiluminescence microscopy of pigmented skin lesions. II. Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol 17: 584–591
Kenet RO, Kang S, Kenet BJ, Fitzpatrick TB, Sober AJ, Barnhill RL (1993) Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy — grading protocol and atlas. Arch Dermatol 129: 157–174
Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, et al. (1988) Thin Stage 1 primary cutaneous malignant melanoma. New Engl J Med 318: 1159–1162
Lyons JH, Cockerell CJ (1994) Elective lymph node dissection for melanoma. J Am Acad Dermatol 30: 467–480
Cochran AJ, Wen DR, Morton DL (1992) Management of the regional lymph nodes in patients with cutaneous malignant melanoma. World J Surg 127: 392
Klaase JM, Kroon BBR, Geel AN van, Eggermont AMM, Franklin HR, Hart AAM (1994) Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 15: 39–45
Kroon BBR (1988) Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 14: 67–78
Cohen J (1993) Cancer vaccines get a shot in the arm. Science 262: 841–843
Hayashi Y, Hoon DSB, Foshag LJ, Park MS, Terasaki PI, Morton DL (1993) A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer 72: 751–759
Morton DL, Foshag LJ, Hoon DSB, Nizze JA, Wanek LA, Chang C, et al. (1992) Prolongation of long-term survival in advanced stage metastatic melanoma following active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463–482
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacKie, R.M. Strategies to reduce mortality from cutaneous malignant melanoma. Arch Dermatol Res 287, 13–15 (1994). https://doi.org/10.1007/BF00370712
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00370712